MicroPhage (Longmont) aims to become a worldwide leader in rapid bacterial diagnostics, both identification and antibiotic susceptibility & resistance testing, through its bacteriophage-based amplification platform for immunoassay diagnostics. The lead Dx products expected in late 2008 are for the identification of methicillin-resitant Staphylococcus aureus (MRSA). Follow-on Dx products for additional bacterial pathogens may include: Vancomycin-resistant [...]

• 251http://clsdf.com/2007/11/microphage-detecting-bugs-in-no-time%e2%80%a6/MicroPhage%3A+Detecting+Bugs+In+No+Time%E2%80%A62007-11-09+04%3A44%3A00admin

You may recall a little over a year ago Endo Pharmaceuticals (NASDAQ: ENDP) acquired RxKinetix whose lead product was RK-0202, a topical oral-rinse with the active ingredient formulated in its proprietary ProGelz® drug delivery platform and was in Phase II.
It sounds as if great progress is being made on RK-0202 which subsequently has become [...]

• 250http://clsdf.com/2007/11/endo-pharma-rxkinetix-enter-piii-trials/Endo+Pharma+%28RxKinetix%29+Enter+PIII+Trials2007-11-08+06%3A07%3A00admin